Abstracts tagged "anti-CCP antibodies"

Abstract Number: 1691 • 2012 ACR/ARHP Annual Meeting
Early Signs of Subclinical Inflammation and Local Antibody Production in Early Rheumatoid Lungs
Gudrun Reynisdottir¹, Reza Karimi², Jimmy Ytterberg³, Vijay Joshua¹, Helga Olsen², Aase Haj Hensvold¹, Anders Harju⁴, Johan Grunewald², Sven Nyren⁵, Anders Eklund², Lars Klareskog⁶, Roman Zubarev⁷, Magnus Skold² and Anca Catrina¹, ¹Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Division of Respiratory Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁵Radiology, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁷Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The aims of the current study was to investigate if inflammatory lung changes are present in RA patients early in the disease process and…
Abstract Number: 31 • 2012 ACR/ARHP Annual Meeting
Anti Citrullinated Protein Antibodies From Synovial Fluid of Rheumatoid Arthritis Patients Enhance Osteoclastogenesis
Akilan Krishnamurthy¹, Nancy Vivar Pomiano², Catia Cerqueira³, Elena Ossipova³, Karin Lundberg⁴, Ulrike Harre⁵, Vivianne Malmström⁶, Per Johan Jakobsson⁷, Lars Klareskog⁸, Georg Schett⁹ and Anca Catrina³, ¹Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁴Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Institute for Clinical Immunology, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁷Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁸Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Presence of anti CCP2 antibodies identifies a subgroup of RA patients that are more prone to develop bone erosions. We hypothesized that anti CCP2…
Abstract Number: 1615 • 2012 ACR/ARHP Annual Meeting
Evidence for Distinct Roles of Environmental and Genetic Factors in the Emergence of Anti Citrullinated-Protein Antibodies Positive Rheumatoid Arthritis-an Epidemiological Investigation in Twins
Aase Haj Hensvold¹, Patrik KE Magnusson², Monika Hansson³, Lena Israelsson⁴, Cecilia Carlens¹, Johan Askling⁵, Vivianne Malmström⁶, Lars Klareskog⁷ and Anca Catrina¹, ¹Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ²Medical Epidemiology and Biostatistics, Swedish Twin Registry Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ⁶Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁷Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
Background/Purpose: The aim of the current study was to investigate the influence of genetic and environmental factors in developing anti citrullianted-proteins antibodies (ACPA) and ACPA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].